Back to search

University of Leeds

Personalisation of therapy in advanced colorectal cancer

Abstract

dc:description.abstract

Personalisation of therapy is an important goal in modern oncology, however routes for biomarker discovery and validation are challenging with a high level of evidence required prior to application into routine care. Whilst cancer care is stratified by biomarker status in some tumour sites, less progress is evident in advanced colorectal cancer (aCRC). In this thesis candidate clinical and molecular biomarkers have been tested within the datasets and biobanks of randomised controlled trials in aCRC (FOCUS, PICCOLO and COIN). Specifically, the utility of routine clinical information as biomarkers, the mechanisms of the poor prognosis of BRAF-mutant aCRC, predictive markers of efficacy for anti-EGFR agents in RAS-wt patients, and testing of pharmacogenomic markers of toxicity and efficacy for irinotecan have been tested. Routinely measured markers of the systemic inflammatory response, the derived neutrophil-lymphocyte ratio and platelet count, were validated as independent adverse prognostic markers in aCRC and may help identify patients who are not disadvantaged more conservative upfront treatment approach. It has been demonstrated that the poor prognosis conferred by BRAF-mutation is mainly driven by rapid progression following first-line therapy, rather than chemo-resistance. Knowledge of BRAF-mutation status therefore provides useful clinical information beyond the context of prognostication and selection for anti-EGFR therapy, with particular implications for treatment sequencing. mRNA overexpression of EGFR ligands and HER3 were both shown to be promising positive predictive markers for anti-EGFR therapy in aCRC in RAS-wt patients. In both studies a population of RAS-wt patients who fail to benefit from anti-EGFR agents were clearly identified. Both markers warrant urgent further validation and clinical development. Therefore further clinical and molecular biomarkers have shown potential clinical utility in aCRC, which all hold promise for routine application and to further personalise treatment in aCRC.

Degree

thesis:*
Name dc:type.qualificationname
Ph.D
Level dc:type.qualificationlevel
doctoral
Grantor dc:publisher.institution
University of Leeds
Year dc:date.issued
2015

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Seligmann, Jennifer Frances
Advisors dc:contributor.advisor
  • Seymour, Matthew
  • Quirke, Philip
  • Richman, Susan

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Identifier
uk.bl.ethos.677289
Dc Identifier Grantnumber
483304

Chain of custody

source
Harvested from
White Rose University Consortium
Base URL
etheses.whiterose.ac.uk/cgi/oai2
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Seligmann, Jennifer Frances. Personalisation of therapy in advanced colorectal cancer. doctoral thesis, University of Leeds, 2015.